FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

November 10, 2026

On the left, GLP-1 weight-loss medications including Wegovy and Ozempic pens and tablets are arranged on a white surface; on the right, a person self-injects into their abdomen.

The FDA has issued an important new Drug Safety Communication that affects every glucagon-like peptide-1 receptor agonist, or GLP-1 RA, on the market. These medications, which include widely used products such as semaglutide, tirzepatide, dulaglutide, and liraglutide, will now carry updated warnings about a potential increased risk of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy, or NAION. For anyone involved with diabetes care, obesity management, or pharmacy practice, this class-wide GLP-1 RA labeling change is a development worth careful attention.

NAION is a

Leave a Reply

Your email address will not be published. Required fields are marked *